Drugmakers are lining up on both sides of the dance floor as the Federal Circuit prepares to hear arguments June 3 in Amgen Inc. v. Sandoz Inc. – the outcome of which could determine when Sandoz launches Zarxio as the first biosimilar in the U.S.